Treatment of pain in Ambulance Services with Sufenta® nasally compared to Morfin® intravenously.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-005366-38-SE

Enrollment

700

Registered

2011-12-13

Start date

2012-02-26

Completion date

Unknown

Last updated

2012-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pain treated in ambulance service.

Interventions

Trade Name: Sufenta Product Name: Sufenta Pharmaceutical Form: Solution for injection Trade Name: Morfin Product Name: Morfin Pharmaceutical Form: Solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in the ambulance service of Stockholm City Council who fulfill the criteria for treatment of pain with opioids according to the local medical guidelines. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 350 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 350

Exclusion criteria

Exclusion criteria: Patientes younger than 18 years of age. Patients unable to participate in measurment of pain with VAS analogue scale. Patients with injuries to face or head making nasal administration not advisable.

Design outcomes

Primary

Measure	Time frame
Main Objective: Study if patients in ambulance services benefits from treatment of pain with Sufenta® nasally instead of the traditional use of Morfin® intravenously.;Secondary Objective: Study if there are benefits for the ambulance team when pain relief treatment is given nasally instead of intravenously.;Primary end point(s): Minutes from time of arrival at the side of the patient to VAS <4. Or if VAS<4 is never reached, VAS measured at the time of arrival at the hospital.;Timepoint(s) of evaluation of this end point: Approximately one month after the data collection, evaluation and analysis will take place.	—

Measure

Time frame

Main Objective: Study if patients in ambulance services benefits from treatment of pain with Sufenta® nasally instead of the traditional use of Morfin® intravenously.;Secondary Objective: Study if there are benefits for the ambulance team when pain relief treatment is given nasally instead of intravenously.;Primary end point(s): Minutes from time of arrival at the side of the patient to VAS <4. Or if VAS<4 is never reached, VAS measured at the time of arrival at the hospital.;Timepoint(s) of evaluation of this end point: Approximately one month after the data collection, evaluation and analysis will take place.

—

Secondary

Measure	Time frame
Secondary end point(s): An enquirie will be sent to the patient asking of his/her opinion of the treatment. The nurse on duty in the ambulance will answer an enquirie at the same time as the patient documentation is accomplished.;Timepoint(s) of evaluation of this end point: Approximately one month after the ambulance transport an enquirie will be sent to the patient. The staff enquirie will be answered at the same time as the patient documentation is accomplished, nearly immediately on arrival at the hospital.	—

Measure

Time frame

Secondary end point(s): An enquirie will be sent to the patient asking of his/her opinion of the treatment. The nurse on duty in the ambulance will answer an enquirie at the same time as the patient documentation is accomplished.;Timepoint(s) of evaluation of this end point: Approximately one month after the ambulance transport an enquirie will be sent to the patient. The staff enquirie will be answered at the same time as the patient documentation is accomplished, nearly immediately on arrival at the hospital.

—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026